Squarepoint Ops LLC raised its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 16.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,747,096 shares of the company’s stock after acquiring an additional 240,597 shares during the quarter. Squarepoint Ops LLC owned approximately 0.06% of LENZ Therapeutics worth $9,924,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of LENZ. BlackRock Inc. bought a new stake in shares of LENZ Therapeutics during the 2nd quarter valued at about $13,019,000. UBS Group AG lifted its stake in shares of LENZ Therapeutics by 36.3% in the 3rd quarter. UBS Group AG now owns 1,201,616 shares of the company’s stock worth $55,971,000 after purchasing an additional 320,135 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of LENZ Therapeutics by 108.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock worth $32,907,000 after purchasing an additional 585,000 shares during the period. Franklin Resources Inc. boosted its holdings in shares of LENZ Therapeutics by 86.7% in the fourth quarter. Franklin Resources Inc. now owns 1,096,334 shares of the company’s stock worth $17,541,000 after buying an additional 509,250 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of LENZ Therapeutics by 307.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,023,542 shares of the company’s stock worth $16,378,000 after buying an additional 772,411 shares during the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.
LENZ Therapeutics Stock Down 3.9%
LENZ stock opened at $4.72 on Friday. LENZ Therapeutics, Inc. has a twelve month low of $4.53 and a twelve month high of $50.40. The stock has a market cap of $148.30 million, a P/E ratio of -1.15 and a beta of 0.66. The business’s 50-day moving average price is $5.24 and its 200-day moving average price is $7.67.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. Piper Sandler cut their target price on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings downgraded shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Tuesday, July 7th. Zacks Research raised shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, LENZ Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $28.80.
Get Our Latest Analysis on LENZ
LENZ Therapeutics Profile
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
- Five stocks we like better than LENZ Therapeutics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Want to see what other hedge funds are holding LENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report).
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
